Home>Topics>Stocks>Intrepid Potash

Intrepid Potash IPI

  1. All
  2. Commentary
  3. Headlines
    1. AbbVie Acquires Pharmacyclics to Solidify Position in Blood Cancer, Diversify Humira Biosimilar Risk

      Commentary

      Thu, 5 Mar 2015

      commercialization of the drug. AbbVie's addition of Imbruvica to its promising clinical-stage blood cancer drugs ABT-199 and IPI -145 positions the company as a leader in the space, particularly given our expectations that combination therapy will be increasingly

    2. Dropping Coverage of Intrepid Potash

      Commentary

      Tue, 12 Aug 2014

      We are dropping analyst coverage of Intrepid Potash . We provide broad coverage of more than 1,500 companies across more than 90 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    3. With a Big Capital Investment Cycle Nearly Complete, Intrepid Should Enjoy Lower Costs Ahead

      Commentary

      Thu, 31 Jul 2014

      We’re raising our fair value estimate for Intrepid Potash to $16 per share from $15 per share following the release of second-quarter results. Our fair value estimate boost reflects

    4. Intrepid's New Solar Solution Mine Will Bring Down Companywide Costs per Ton

      Commentary

      Thu, 1 May 2014

      We're holding steady on our $15-per-share fair value estimate for Intrepid Potash following the release of the company's first-quarter results. Our no-moat rating remains intact. Despite a big jump in

    5. Potash Cartel Is on the Mend; We Expect to Boost Fair Value Estimates for Potash Producers

      Commentary

      Thu, 6 Mar 2014

      heavily on fertilizer mix at the individual company level. For example, the effect will be much greater on pure-play Intrepid Potash than diversified Agrium. We also expect to re-examine other parts of our valuations for potash producers when implementing

    6. Intrepid Battles Lower Potash Prices and Weak Volumes; Maintaining Our Fair Value Estimate

      Commentary

      Thu, 13 Feb 2014

      We're holding steady on our $13 per share fair value estimate for Intrepid Potash following the release of the firm's full-year results and forecast for 2014. Our no moat rating remains intact. The firm

    7. We're Lowering our Fair Value Estimate for Intrepid Potash

      Commentary

      Fri, 8 Nov 2013

      We're lowering our fair value estimate for Intrepid Potash to $13 per share from $14 following the release of its third-quarter results and adjustments to our near-term and long

    8. Intrepid Potash shares jump as Koch discloses larger stake

      Headlines

      Mon, 4 Nov 2013

      (Reuters) - Shares of Intrepid Potash Inc , a U.S. producer of the crop nutrient potash, jumped nearly 11 percent on Monday after privately held Koch Industries Inc said it had upped its stake in the...

    9. K+S Proceeding With Greenfield Potash Project

      Commentary

      Tue, 6 Aug 2013

      change our new potash price assumption of $300 per ton or our new fair value estimates for PotashCorp, Compass Minerals, Intrepid Potash , SQM, and Mosaic. We actually opted to include the first phase of Legacy's production in our updated global supply

    10. Uralkali to Leave Belarus Potash Company; Potash Producers Under Review

      Commentary

      Tue, 30 Jul 2013

      Mosaic MOS, Agrium AGU, Intrepid Potash IPI , K+S, SQM SQM, and Compass ..... narrow moat ratings for SQM and Intrepid Potash , as this announcement tests ..... Compass Minerals, $68; Intrepid Potash , $8; Mosaic, $30; Agrium

    « Prev1234Next »
    Content Partners